Read more
In some countries such as the United States, kidney disease kills more people than cancers of the prostate or breast. In the United States for example there are over 15 million individuals with kidney disease. Translated to a worldwide basis, kidney disease of various aetiologies represent a significant burden on healthcare systems, affecting mortality, morbidity and also the family unit. It is therefore imperative that appropriate use is made of conventional, new and emerging biomarker platforms to aid diagnosis, treatment and an understanding of outcome measures. Biomarkers in Kidney Disease embraces a holistic approach by combining information on different conditions that affect the kidney and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge and trends. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.
List of contents
Biomarkers in kidney transplantationHypoxia as a Biomarker of Kidney Disease
Random Spot Urine Markers for Kidney and Their Applications
Urinary Angiotensinogen as a Biomarker for Renal Disease
BLyS and APRIL Cytokines as Biomarkers of Kidney Diseases
Plasma Growth Arrest-Specific Protein 6 (Gas6) as a Biomarker of Renal Diseases
Salivary urea nitrogen as a biomarker for renal dysfunction
Biomarkers in IgA Nephropathy
Malondialdehyde as a biomarker in kidney transplantation
Planar Antibody Arrays for Biomarkers in Nephritis
Next Generation Sequencing (NGS) in biomarker discovery and applications in Nephrology
M-type phospholipase A2 receptor as a biomarker in kidney disease
Aortic pulse wave velocity as a biomarker in chronic dialysis patient
Red Blood Cell Distribution Width: Useful Predictor for Treatment Response in Primary Glomerular Diseases
About the author
Professor Victor R. Preedy is a senior faculty member of King's College London (Professor of Nutritional Biochemistry) and King's College Hospital (Professor of Clinical Biochemistry). He is attached to both the Diabetes and Nutritional Sciences Division and the Department of Nutrition and Dietetics. He is also Director of the Genomics Centre and a member of the School of Medicine. Professor Preedy graduated in 1974 with an Honours Degree in Biology and Physiology with Pharmacology. He gained his University of London PhD in 1981. In 1993 he gained his second doctoral degree, for his outstanding contribution to protein metabolism in health and disease. He has received membership and fellowship of a number of academic and professional bodies in the UK, including the Royal College of Pathologists, the Royal Institute of Public Health, and the Royal Society of Chemistry. Professor Preedy has published over 570 articles, which includes 165 peer-reviewed manuscripts based on original research, 100 reviews, and over 50 books and book volumes.
Summary
In some countries such as the United States, kidney disease kills more people than cancers of the prostate or breast. In the United States for example there are over 15 million individuals with kidney disease. Translated to a worldwide basis, kidney disease of various aetiologies represent a significant burden on healthcare systems, affecting mortality, morbidity and also the family unit. It is therefore imperative that appropriate use is made of conventional, new and emerging biomarker platforms to aid diagnosis, treatment and an understanding of outcome measures. Biomarkers in Kidney Disease embraces a holistic approach by combining information on different conditions that affect the kidney and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge and trends. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.
